#USA #Duluth #Bridge to Life #VitaSmart™ #organ preservation

Bridge to Life's Innovative VitaSmart™ HOPE System

In a significant advancement for organ transplantation, the VitaSmart™ HOPE perfusion system, developed by Bridge to Life, has been validated as a superior organ preservation technology. A comprehensive study published in the prestigious JAMA Surgery journal sheds light on how this innovative system enhances the viability of organs harvested from donors, thus expanding the availability of transplants for patients suffering from end-stage organ failure.

Groundbreaking Study Details

The multi-center clinical trial, aptly named Bridge to HOPE, is the first randomized study of its kind conducted in the United States to evaluate the clinical impact of hypothermic oxygenated perfusion (HOPE) in liver transplants from high-risk donors. The study involved 219 recipients across 15 transplant centers and focused on utilizing marginal donor organs—specifically those from donors with brain death (DBD) and circulatory death (DCD). By employing the VitaSmart™ HOPE system, this research revealed that advanced preservation techniques can significantly improve post-transplant outcomes and align with the urgent need for more organ transplants in the U.S., where over 100,000 patients await lifesaving procedures.

Clinical Outcomes and FDA Approval

The findings from the Bridge to HOPE study show meaningful increases in the usage rates of donor organs, emphasizing the role of the VitaSmart technology in making more organs available for transplant. With the successful completion of this study, Bridge to Life has secured a De Novo FDA approval for the VitaSmart™ HOPE system. This regulatory green light establishes a new pathway for organ preservation practices and sets a robust foundation for its introduction into clinical settings.

Mauricio Carvalho, Vice President of Medical Affairs at Bridge to Life, articulated the transformative potential of the VitaSmart technology for the transplant community. He mentioned that "the HOPE perfusion offers a straightforward, safe, and clinically beneficial preservation strategy that could serve as a scalable alternative to normothermic machine perfusion. This is particularly crucial in an operational context where perfusion infrastructure is limited".

The implications of this study are profound. For example, general complications associated with liver transplants were significantly lower with the introduction of the HOPE methodology which identifies VitaSmart as a feasible solution addressing current organ transplant challenges.

Industry Perspectives

The CEO of Bridge to Life, Don Webber, expressed enthusiasm over the scholarly validation of their technology, emphasizing the need to eliminate operational hurdles that have restricted the use of perfused organs in the U.S. transplant ecosystem. He noted, "Despite this technology's clinical validation, a mere fraction of the livers transplanted in the U.S. underwent machine perfusion due to operational complexities and costs. Our focus is to provide a seamless solution, ensuring the success and adoption of the VitaSmart™ HOPE system in transplant workflows."

Conclusion

Bridge to Life™ Ltd is at the forefront of delivering market-leading organ preservation solutions, including the highly regarded VitaSmart™ system. As institutions seek to enhance their transplant capabilities amidst increasing demand, the comprehensive evidence supporting the efficacy and safety of the VitaSmart™ HOPE system provides a promising path forward. This study aligns with Bridge to Life's commitment to innovation and accessibility, placing them in a pivotal role as they collaborate with leading transplant centers and organ procurement organizations globally.

For more information about the study, please refer to the original publication in JAMA Surgery here.